Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 12/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 6/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.37 |
| ▸ | GABRD | O14764 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30521521 | 1.00 | ACACB (0.47) | ACACBALDH1A1CHRNA7PDE10APIK3CD | |
| SCHEMBL24774420 | 0.85 | ACACB (0.39) | ACACBALDH1A1CHRNA7 | |
| SCHEMBL30134001 | 0.85 | ACACB (0.39) | ACACBALDH1A1CHRNA7 | |
| SCHEMBL11951668 | 0.84 | ALDH1A1 (0.49) | ACACBALDH1A1CHRNA7PDE10APIK3CD | |
| SCHEMBL1581887 | 0.82 | NNMT (0.46) | ALDH1A1CHRNA7 | |
| SCHEMBL30108570 | 0.82 | NNMT (0.46) | ALDH1A1CHRNA7 | |
| SCHEMBL9988098 | 0.81 | ALDH1A1 (0.46) | ACACBALDH1A1CHRNA7PDE10APIK3CD | |
| SCHEMBL29483296 | 0.81 | ALDH1A1 (0.46) | ACACBALDH1A1CHRNA7PDE10APIK3CD | |
| SCHEMBL14480140 | 0.81 | ALDH1A1 (0.46) | ACACBALDH1A1CHRNA7PDE10APIK3CD | |
| SCHEMBL19440237 | 0.81 | ALDH1A1 (0.46) | ACACBALDH1A1CHRNA7PDE10APIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327417-A1 | HETEROCYCLIC COMPOUNDS | BEIGENE SWITZERLAND GMBH (CH) | 2024-10-03 | — | — | US | disclosed |
| CN-112654621-B | Substituted naphthyridinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-3814348-B9 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3814348-B1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3814348-B1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2023125681-A1 | HETEROCYCLIC COMPOUNDS | BEIGENE, LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023125681-A1 | HETEROCYCLIC COMPOUNDS | BEIGENE, LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3814348-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-112654621-A | Substituted naphthyridinone compounds useful as T cell activators | 百时美施贵宝公司 | 2021-04-13 | — | — | CN | disclosed |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-02 | — | — | US | disclosed |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2020-04-09 | — | — | US | disclosed |
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | ACACB 3650/4885ALDH1A1 3814/4885CHRNA7 3473/4885 |
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | ACACB 3650/4885ALDH1A1 3814/4885CHRNA7 3473/4885 |
| US-20240327417-A1 | HETEROCYCLIC COMPOUNDS | NFATC1, CD4, ACIN1 | ACACB 610/4885ALDH1A1 1006/4885CHRNA7 3045/4885 |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | ACACB 3650/4885ALDH1A1 3814/4885CHRNA7 3473/4885 |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | ACACB 3650/4885ALDH1A1 3814/4885CHRNA7 3473/4885 |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | ACACB 3650/4885ALDH1A1 3814/4885CHRNA7 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.